查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1510433

溶瘤病毒免疫治療市場- 按病毒類型（HSV、腺病毒、痘苗病毒、呼腸孤病毒）、應用（黑色素瘤、乳腺癌、前列腺癌）、給藥途徑（腫瘤內、靜脈內）、最終用戶- 全球預測2024 - 2032

Oncolytic Virus Immunotherapy Market - By Virus Type (HSV, Adenovirus, Vaccinia Virus, Reovirus), Application (Melanoma, Breast Cancer, Prostate Cancer), Route of Administration (Intratumoral, Intravenous), End-user - Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於該領域的研究和開發不斷增加，2024 年至 2032 年全球溶瘤病毒免疫治療市場的複合年成長率將達到 22.6%。溶瘤病毒免疫療法是一種有前途的癌症治療方法，涉及使用病毒選擇性地靶向和殺死癌細胞，同時保護健康組織。最近在理解病毒與宿主相互作用、基因工程和免疫學方面取得的進展導致了更有效的溶瘤病毒的開發。

例如，2024 年 4 月，有人推測將免疫療法與旨在攻擊癌細胞的病毒相結合可能為治療神經內分泌腫瘤（一種發病率不斷增加的罕見癌症）提供一種有前景的方法。由邁阿密大學米勒醫學院西爾維斯特綜合癌症中心領導的一項正在進行的研究的數據在美國癌症研究協會會議上發表。

這些病毒經過改造可增強其腫瘤選擇性特性並刺激免疫系統產生抗癌反應。隨著正在進行的臨床試驗顯示出有希望的結果以及幾種溶瘤病毒療法的批准，對此類治療的需求正在增加，因為它們為改善癌症患者的治療結果帶來了希望。

溶瘤病毒免疫治療產業的整體規模根據病毒類型、應用、給藥途徑、最終用途和地區進行分類。

腺病毒細分市場將在 2024 年至 2032 年實現突破性成長。腺病毒透過選擇性地靶向和破壞癌細胞，同時不傷害健康細胞，在癌症治療中顯示出了前景。使用基於腺病毒的療法的臨床試驗已證明在各種類型的癌症中取得了令人鼓舞的結果。基於腺病毒的免疫療法刺激免疫系統識別和攻擊癌細胞，提供了潛在有效的治療選擇。隨著研究不斷揭示基於腺病毒的療法的全部潛力及其對抗癌症的有效性，溶瘤病毒免疫療法市場對這些創新療法的需求正在穩步成長。

2024年至2032年，腫瘤內領域的溶瘤病毒免疫治療市場佔有率將出現顯著的複合年成長率。這種有針對性的方法可以最大限度地減少全身副作用並提高治療效果。臨床試驗已證明腫瘤內溶瘤病毒免疫療法在多種癌症（包括黑色素瘤和晚期實體瘤）中的潛力。隨著研究人員不斷探索新的病毒載體和聯合療法，對腫瘤內溶瘤病毒治療的需求不斷成長。它們為個人化癌症治療提供了一條有前途的途徑，代表了癌症治療的重大進步。

2024年至2032年，歐洲溶瘤病毒免疫治療市場將呈現顯著的成長速度。歐洲的臨床試驗和研究計畫正在探索溶瘤病毒靶向和破壞癌細胞同時增強針對腫瘤的免疫反應的潛力。隨著病毒工程和治療策略的進步，歐洲醫療保健提供者熱衷於採用溶瘤病毒免疫療法，為患者提供更有效和個人化的治療選擇。這種不斷成長的需求凸顯了溶瘤病毒療法在歐洲癌症治療領域的重要性。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 癌症發生率上升
      • 越來越關注聯合療法
      • 研發投資不斷增加
      • 病毒工程不斷進步
    • 產業陷阱與挑戰
      • 免疫原性和治療抗藥性的發展
      • 與治療相關的高成本和風險
  • 成長潛力分析
  • 管道分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按病毒類型，2021 - 2032 年

  • 主要趨勢
  • 單純皰疹病毒（HSV）
  • 腺病毒
  • 牛痘病毒
  • 新城疫病毒
  • 呼腸孤病毒
  • 其他病毒類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 瘤內
  • 靜脈
  • 其他給藥途徑

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 黑色素瘤
  • 乳癌
  • 肺癌
  • 卵巢癌
  • 攝護腺癌
  • 其他應用

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

  • 主要趨勢
  • 醫院和診所
  • 癌症研究機構
  • 門診手術中心
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Amgen Inc.
  • Creative Biolabs
  • Daiichi Sankyo Company Limited
  • Genelux Corporation
  • Oncorus Inc.
  • Replismune Inc.
  • Siga Technologies
  • Sorrento Therapeutics Inc.
  • TILT Biotherapeutics
  • Viralytics Ltd.
簡介目錄
Product Code: 8770

Global Oncolytic Virus Immunotherapy Market will witness 22.6% CAGR between 2024 and 2032 due to increasing research and development in the field. Oncolytic virus immunotherapy, a promising approach in cancer treatment, involves using viruses to target and kill cancer cells selectively while sparing healthy tissue. Recent advancements in understanding virus-host interactions, genetic engineering, and immunology have led to the development of more effective oncolytic viruses.

For instance, in April 2024, it was speculated that combining immunotherapy with a virus designed to attack cancer cells may offer a promising approach to treating neuroendocrine tumors, a rare cancer with increasing incidence. Data from an ongoing study led by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine was presented at the American Association for Cancer Research Meeting.

These viruses are engineered to enhance their tumor-selective properties and stimulate the immune system to mount an anti-cancer response. With ongoing clinical trials showing promising results and the approval of several oncolytic virus therapies, the demand for such treatments is escalating as they offer hope for improved outcomes in cancer patients.

The overall Oncolytic Virus Immunotherapy Industry size is classified based on the virus type, application, route of administration, end-use, and region.

The adenovirus segment will record breakthrough growth over 2024-2032. Adenoviruses have shown promise in cancer treatment by selectively targeting and destroying cancer cells while leaving healthy cells unharmed. Clinical trials using adenovirus-based therapies have demonstrated encouraging results in various types of cancer. Adenovirus-based immunotherapies stimulate the immune system to recognize and attack cancer cells, offering a potentially potent treatment option. As research continues to uncover the full potential of adenovirus-based therapies and their effectiveness in combating cancer, the demand for these innovative treatments in the oncolytic virus immunotherapy market is increasing steadily.

The oncolytic virus immunotherapy market share from the intratumoral segment will register a notable CAGR from 2024 to 2032. Intratumoral therapy involves directly injecting oncolytic viruses into tumors, triggering a localized immune response against cancer cells. This targeted approach minimizes systemic side effects and enhances treatment efficacy. Clinical trials have demonstrated the potential of intratumoral oncolytic virus immunotherapy in various cancers, including melanoma and advanced solid tumors. As researchers continue to explore new viral vectors and combination therapies, the demand for intratumoral oncolytic virus treatments is growing. They offer a promising avenue for personalized cancer therapy and represent a significant advancement in cancer treatment.

Europe oncolytic virus immunotherapy market will exhibit a noteworthy growth rate from 2024 to 2032. As European countries increasingly prioritize innovative cancer therapies, oncolytic virus immunotherapy stands out as a promising approach. Clinical trials and research initiatives in Europe are exploring the potential of oncolytic viruses to target and destroy cancer cells while boosting the immune response against tumors. With advancements in viral engineering and treatment strategies, European healthcare providers are keenly adopting oncolytic virus immunotherapy to offer patients more effective and personalized treatment options. This growing demand underscores the significance of oncolytic virus therapies in the European cancer treatment landscape.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer
      • 3.2.1.2 Increasing focus towards combination therapies
      • 3.2.1.3 Rising R&D investments
      • 3.2.1.4 Growing advancements in viral engineering
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Development of immunogenicity and resistance to the treatment
      • 3.2.2.2 High cost and risk associated with the treatment
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Herpes simplex virus (HSV)
  • 5.3 Adenovirus
  • 5.4 Vaccinia virus
  • 5.5 Newcastle disease virus
  • 5.6 Reovirus
  • 5.7 Other virus types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Intratumoral
  • 6.3 Intravenous
  • 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Melanoma
  • 7.3 Breast cancer
  • 7.4 Lung cancer
  • 7.5 Ovarian cancer
  • 7.6 Prostate cancer
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Cancer research institutes
  • 8.4 Ambulatory surgical centers
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Amgen Inc.
  • 10.2 Creative Biolabs
  • 10.3 Daiichi Sankyo Company Limited
  • 10.4 Genelux Corporation
  • 10.5 Oncorus Inc.
  • 10.6 Replismune Inc.
  • 10.7 Siga Technologies
  • 10.8 Sorrento Therapeutics Inc.
  • 10.9 TILT Biotherapeutics
  • 10.10 Viralytics Ltd.